FDA expectations for oral liquid dosing devices, and the dosing errors behind them

Oral liquid drug products are among the most error-prone dosage forms in real-world use, particularly for pediatric patients. A caregiver has to translate a written dose into a measured volume, and every point in that chain (the unit of measure, the markings on the device, whether a device is even supplied) is a place where the dose can go wrong. FDA's expectations for the measuring device that accompanies an oral liquid product are built directly on that error history. This overview summarizes what FDA asks sponsors and manufacturers to do, and the specific dosing-error patterns that drove those recommendations.

The core principle: the device is labeling, and it must agree with the label

FDA treats the markings on a dosage delivery device as labeling, not as an incidental accessory. The practical consequence is a concordance requirement: if the bottle or carton directions state a dose in a given unit, the device supplied with the product must be calibrated in that same unit ⁷⁶. A device whose markings are inconsistent with the labeled directions can render the product misbranded, and a device that fails to bear liquid-measure marks consistent with the labeled dosing directions can leave the product without adequate directions for use ³⁴.

FDA's central recommendations for the device itself, set out in the 2011 guidance Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products, are:

Supply a device with every orally ingested OTC liquid product. FDA expects an appropriate measuring device to be included, rather than leaving the patient to find one ³.
Match the device unit to the labeled dose. The calibrated units on the device should be the same units used in the labeled directions, whether teaspoon, tablespoon, or milliliter, and the device should deliver the product in a volumetric unit consistent with the recommended dose ¹⁹.
Use consistent language and abbreviations. Avoid mismatches such as "teaspoon" on the label versus "tsp" on the device; if an abbreviation is used, use it consistently across the label and the device ⁴⁹.
Include only the markings that are needed. Markings should cover the labeled doses without superfluous or extraneous graduations that could confuse the user ¹⁹.
Size the device to the dose range. The device should not be significantly larger than the largest labeled dose, while still allowing the smallest labeled dose to be measured clearly ⁹.
Keep markings legible in use. Liquid-measure markings should be clearly visible and not obscured by the liquid when the dose is measured ⁷.
Restrict to oral use. For oral liquid products, FDA recommends the device bear a statement such as "For Oral Administration Only" or "For Oral Use Only" ²³.
Test usability. FDA recommends usability studies to confirm the device is easily understood and can be used to measure doses accurately ⁷.

The shift to metric (mL) dosing

A recurring theme across FDA's medication-error guidances is the move away from household and apothecary measures toward metric units. FDA recommends that oral liquid dosing use metric units, with mL as the standard unit of measure on both the container label and the dosing device, and it specifically advises against household or apothecary measures such as teaspoon, tablespoon, drams, or grains ¹¹⁶. An oral syringe, for example, should be calibrated in milliliters rather than in milligrams ¹.

To support that metric approach and to prevent 10-fold and misread doses, FDA's labeling and product-design guidances recommend defining abbreviations (for example, defining "tsp"), using a leading zero before a decimal point, avoiding trailing zeros, and using clear fraction notation ⁹. For pediatric acetaminophen oral liquids in particular, FDA recommends that dosing directions be expressed in mL and that the delivery device be calibrated in mL only ².

The dosing errors that drove these expectations

FDA's device and labeling recommendations are a direct response to documented harm. The error patterns fall into a few consistent buckets.

Unit mismatch between the device and the directions. FDA's product-design guidance cites reports of dosing errors when an oral dosing device was marked in milligrams while the dose was prescribed in milliliters, leaving the patient unable to measure the intended volume ⁶. Inconsistent or confusing units in the directions (cc, mL, tsp, tbsp) were identified as a contributor to overdose risk ¹⁷.

No device supplied, so patients improvise. When an appropriate measuring device is not packaged with the product, people fall back on household spoons, which vary widely in volume and cause both under- and overdosing ⁶¹⁷. FAERS reports illustrate the endpoint of this problem: BENADRYL cases describing ingestion of "the entire 4 ounce bottle," "half a bottle," or an "unknown amount," consistent with no proper measuring device being used ⁶⁶⁶⁸⁷¹.

Wrong device or wrong technique. FAERS reports document doses given with the wrong device (AUGMENTIN ES-600) ⁷⁴, a caregiver "using his own dosing cup" with CHILDREN'S MOTRIN ⁷², and "wrong technique in drug usage" with an oral memantine solution ⁷³. Cup-related administration problems appear across metoclopramide, levetiracetam, and other oral liquids ⁶²⁶⁴.

Teaspoon-based dosing and household-measure confusion. Reports describe pediatric suspensions dosed as "1 teaspoon" or "1 teaspoonful" (TRIOTANN, PHENCHLOR TANNATE) and "1/4 teaspoon" (BENYLIN pediatric dextromethorphan), the imprecise measures FDA's metric recommendation is meant to displace ⁶⁷⁷⁶. More recent reports still show volume-based errors, such as an accidental overdose with propranolol hydrochloride oral solution measured in milliliters ⁷⁹.

Accidental overdose as the clinical outcome. Across these oral liquid reports the recurring adverse-event terms are accidental overdose, incorrect dose administered, and medication error, including infant's acetaminophen oral drops, oxycodone oral solution, theophylline elixir, and a Claritin oral solution case flagged as a circumstance capable of leading to a medication error ⁵⁸⁵⁹⁶⁰⁶¹⁶³⁷³.

Pediatric acetaminophen: the case study behind the guidance

The clearest driver of FDA's thinking is the pediatric acetaminophen experience. FDA identified several overlapping sources of confusion: multiple pediatric formulations at different concentrations; confusion between concentrated infant drops (80 mg/0.8 mL and 80 mg/mL) and children's oral liquid (160 mg/5 mL); simultaneous use of two acetaminophen-containing products; inconsistent units in the directions; and dosing devices that were either not packaged with the product or too poorly designed to allow precise, readable dosing ¹⁷⁸⁹.

Because multiple concentrations caused errors among both consumers and healthcare professionals, advisory committees recommended moving to a single standardized pediatric concentration, and the Consumer Healthcare Products Association proposed phasing out the concentrated infant drops in favor of the 160 mg/5 mL product ⁸⁹. FDA's resulting recommendations were that OTC pediatric acetaminophen oral liquids be formulated, packaged, labeled, and supplied with an appropriate dosing device, that a single 160 mg/5 mL concentration be used, and that both the directions and the device be expressed in mL only ¹⁷⁸⁹².

Flow restrictors: limiting harm when a child gets the bottle

A related expectation addresses accidental ingestion rather than measured dosing. FDA notes that children younger than 6 account for more than 9,500 emergency department visits each year from unintentional ingestion of oral liquid drug products ⁸⁸. In its 2020 guidance on flow restrictors, FDA recommends that manufacturers consider combining child-resistant packaging with a restricted delivery system, such as a flow restrictor, to further reduce unintentional ingestion ⁸⁸. Flow restrictors limit how much liquid a child can extract from a bottle; in the studies FDA cites, they prevented 3- and 4-year-olds from emptying bottles quickly and were associated with lower average doses in accidental liquid acetaminophen ingestions ²⁷. FDA is explicit that a flow restrictor is a complement to child-resistant packaging, not a replacement for it ⁸⁸.

What this means for a submission or product-design review

For an oral liquid product, the device is part of the labeling and should be reviewed as such. The practical checkpoints that follow from FDA's guidances are: a device is supplied with the product; the device unit matches the labeled dose unit (metric/mL preferred); markings cover the labeled doses and nothing extraneous; the device is sized so both the smallest and largest labeled doses can be measured clearly; abbreviations, decimals, and fractions follow the medication-error conventions; markings stay legible when liquid is present; an oral-use-only statement is included; and usability testing supports accurate real-world measurement ¹³⁴⁷⁹²³. For pediatric products, concentration standardization and mL-only dosing carry additional weight ²⁸⁹, and for products with meaningful pediatric accidental-ingestion risk, a flow restrictor layered on top of child-resistant packaging is worth evaluating ⁸⁸.